Hepatology

The RED-C clinical trial program highlights the promising potential of the rifaximin soluble solid dispersion immediate-release tablets for delaying early HE-related decompensation.

Novo Nordisk announced the topline findings from the pivotal ESSENCE trial and intends to file applications in early 2025 with US and EU regulators.

Rifaximin monotherapy may also confer a survival benefit, according to the study, which was awarded ACG Outstanding Research Award in the Liver Category.

EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.

Your daily dose of the clinical news you may have missed.

More than 50% of patients with MASH receiving 1 of 3 doses of tirzepatide achieved MASH resolution without worsening of fibrosis vs placebo, according to data from phase 2 study.

Your daily dose of the clinical news you may have missed.

ENDO 2024. New findings suggest GLP-1RAs and SGLT-2is may be more beneficial than other diabetes agents for patients with T2D and MASLD.

Your daily dose of the clinical news you may have missed.

DDW 2024. Offspring with both parents with overweight had a nearly 3-fold increased risk of MASLD in young adulthood, according to new data.

DDW 24. New research shows patients with MASLD and T2D who used GLP-1 agonists had a reduced risk of progression to cirrhosis and HCC vs non-users.

Following the landmark FDA approval of resmetirom for MASH with fibrosis, hepatologist and researcher Alkhouri describes more mid- and late-stage candidates.

Hepatologist Naim Alkhouri, MD, offered 3 take-home thoughts for primary care colleagues to help increase early detection of MASLD.

Naim Alkhouri, MD, a transplant hepatologist and a resmetirom investigator, talks here about the life-changing impact the drug will have for all touched by MASH.

Primary care is where early detection and treatment of liver disease should begin and as Dr Alkhouri highlights here, all the right tools are already at hand.

The national study on the true prevalence of metabolic dysfunction-associated liver disease is essential to screening, prevention, and treatment efforts, says AFL CEO Stiehl.

Alkhouri, a veteran investigator in the field of hepatic disease, including MASLD and MASH, stresses the need for early detection of MASLD when simple intervention can be effective.

Resmetirom to treat NASH with F2-F3 fibrosis, the only approved therapy, is available through Madrigal's specialty pharmacy network, the company said.

LEGEND phase 2 interim analysis findings include significant decreases in HbA1c in poorly controlled T2D and positive effects on several markers of liver injury.

Your daily dose of the clinical news you may have missed.

Resmetirom is the first-ever drug to be approved anywhere for management of the progressive liver disease.

Ionis reports the first clinical evidence that DGAT2 inhibition-driven reduction of hepatic fat correlates with improvements in MASH histologic endpoints.

The 2 phase 3 trials in the 89bio ENLIGHTEN clinical trial program will evaluate the safety and efficacy of the FGF21 analog in MASH, fibrosis.

Authors: Exclusion of people with CKD from CV medication trials has left significant gaps in understanding the effectiveness of these drugs in a highly vulnerable population.

Resmetirom vs placebo led to significantly greater proportion of adults reaching NASH resolution without increased fibrosis and with fibrosis improvement by ≥1 stage.